MBD6

Across TCGA pan-cancer cohorts, MBD6 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of MBD6’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where MBD6 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MBD6 is over-expressed in tumor, although a few such as CCRCC and LUAD show the opposite, repressed pattern.

CCRCC, LUAD, and HNSC are the cancer types where MBD6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MBD6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	II,III,IV	−0.938	.032	3	view →
LUAD	Female	All	−0.604	.026	1	view →
HNSC	Male	III,IV	−0.232	.010	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

MBD6–CCRCC

Open the CCRCC breakdown →